![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 24, 2022
The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021
The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
September 30, 2021
Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH
July 7, 2021
Recent ECOG-ACRIN trial updates and results
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
April 27, 2021
In this interview, Dr. Peter O'Dwyer urges physicians, sites, and testing laboratories to redouble efforts to locate patients for 12 open arms
January 25, 2021
Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
October 19, 2020
The Journal of Clinical Oncology published new data from the NCI-MATCH precision medicine cancer trial that has broad relevance in medicine and provides a roadmap for future precision medicine trials
January 13, 2020
